Current clinical practice guidelines for the early detection of PCa recommend a personalized prostate-specific antigen (PSA)-based management for clinical decision-making to improve the risk–benefit ratio of a screening strategy [2]. The gene discussed is KLK3; the disease is posterior cortical atrophy.